esophageal squamous cell carcinoma
Mar 07, 2025
TEVIMBRA’s Winning Streak — BeiGene Secures New Indication for PD-1 Drug
On March 3, 2025, BeiGene secured another approval for its anti-PD-1 antibody, TEVIMBRA, as the FDA granted clearance for its use in combination with platinum-based chemotherapy as a first-line treatment for adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1....
Read More...
-Agonist.png "Toll-like Receptors Agonist")
